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CPT-11 (irinotecan) is a DNA-topoisomerase I inhibitor with preclinical activity against neuroblastoma (NB) xenografts. The aim was
to establish in vivo an NB xenograft resistant to CPT-11 in order to study the resistance mechanisms acquired in a therapeutic setting.
IGR-NB8 is an immature NB xenograft with MYCN amplification and 1p deletion, which is sensitive to CPT-11. Athymic mice bearing
advanced-stage subcutaneous tumours were treated with CPT-11 (27mgkg
 1day
 1 5) every 21 days (1 cycle) for a maximum of
four cycles. After tumour regrowth, a new in vivo passage was performed and the CPT-11 treatment was repeated. After the third
passage, a resistant xenograft was obtained (IGRNB8-R). The tumour growth delay (TGD) was reduced from 115 at passage 1 to 40
at passage 4 and no complete or partial regression was observed. After further exposure to the drug, up to 28 passages, the resistant
xenograft was definitively established with a TGD from 17 at passage 28. Resistant tumours reverted to sensitive tumours after 15
passages without treatment. IGR-NB8-R remained sensitive to cyclophosphamide and cisplatin and cross-resistance was observed
with the topoisomerase I inhibitor topotecan. No quantitative or qualitative topoisomerase I modifications were observed. The level
of expression of multidrug resistance 1 (MDR1), MDR-associated protein 1 (MRP1) and, breast cancer resistance protein, three
members of the ATP-binding cassette transporter family was not modified over passages. Our results suggest a novel resistance
mechanism, probably not involving the mechanisms usually observed in vitro.
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Irinotecan (CPT-11), a semisynthetic water-soluble analogue of
camptothecin, belongs to a new family of anticancer drugs, the
DNA-topoisomerase I inhibitors. Topoisomerase I is an essential
nuclear enzyme that relaxes DNA torsional tension during
fundamental processes such as replication, transcription, recom-
bination and repair, and represent a target for many anticancer
drugs. Irinotecan settles on the DNA-topoisomerase I complex
(cleavable complex), stabilises it and inhibits the religation of
DNA. Cytotoxicity arises during the replication process when the
advancing replication fork and cleavable complex collide, leading
to irreversible DNA damage and to the initiation of a series of
events that result in cell death (Chen and Liu, 1994; Pommier,
1996).
Neuroblastoma (NB) is one of the most common solid tumours
in young children and is responsible for approximately 7.5% of all
cancer among children younger than 15 years of age (Ries et al,
1999). It is a neural crest-derived embryonal cancer of the
sympathetic nervous system. Biological parameters such as MYCN
gene amplification (Brodeur et al, 1984), loss of heterozygosity of
chromosome 1p (Fong et al, 1989), (Hayashi et al, 1989) diploidy
(Look et al, 1991) and MDR1 gene overexpression (Bourhis et al,
1989) have been identified as strong predictors of a poor outcome.
CPT-11 has demonstrated antitumour activity against a wide
spectrum of both adult and paediatric xenografts in preclinical
studies (Komuro et al, 1994; Vassal et al, 1996; Thompson et al,
1997a). We have previously shown that i.v. treatment with
CPT-11 resulted in extensive tumour regression and growth delay
in three different NB xenograft models (Vassal et al, 1996).
Similarly, Thompson et al (1997b) showed that oral CPT-11 was
active against a panel of six NB xenografts. Similar effects
have been reported for the topoisomerase I inhibitor topotecan,
which induced tumour regression and a significant tumour growth
delay (TGD) in animals bearing NB xenografts (Vassal et al, 1997).
CPT-11 is currently evaluated in children with NB using several
doses and schedules, such as 600mgm
 2 every 3 weeks, 50mgm
 2
day
 1 5 every 3 week or 20mgm
 2day
 1 5 weekly for 2 weeks
in a row every 3 weeks (Furman et al, 1999; Blaney et al, 2001;
Vassal et al, 2003a).
The emergence of drug resistance in cancer is a major hurdle to
successful chemotherapy. Drug resistance has been described in a
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snumber of cell lines selected for their resistance to topoisomerase I
inhibitors. These studies have shown that quantitative and
qualitative changes in topoisomerase I can induce a resistance to
topoisomerase I poisons (Li et al, 1996; Rubin et al, 1996). To date,
resistance to CPT-11 has been studied mainly in vitro, a situation
in which most of the variables are controlled. As this controlled
situation cannot be equated with that likely to occur in a
therapeutic setting, we established in vivo an NB xenograft model
resistant to CPT-11, in order to study the mechanisms involved in
acquired resistance in this context. It is believed that concrete
results thus evidenced can be better translated into clinical
applications.
MATERIAL AND METHODS
Drugs
CPT-11 was provided by Aventis Pharma SA (Vitry-sur-Seine,
France). Cyclophosphamide was purchased from Asta-Medica
(Me ´rignac, France), cisplatin from Bellon and etoposide from
Novartis (Rueil-Malmaison, France). Drugs were dissolved in a
0.9% sodium chloride solution immediately before injection on
each day of treatment.
Animals
Female specific pathogen-free Swiss athymic mice (6–8 weeks old)
were bred in the Animal Experimentation Unit of the Institut
Gustave-Roussy. Animals were housed in sterile isolators and fed
with irradiated nutriments (UAR, Villemoisson/Orge, France) and
filtered water. Experiments were carried out under the conditions
established by the European Community directive no. 86/609/.CEE
and in accordance with the UKCCCR guidelines (Workman et al,
1998).
NB xenograft
IGR-NB8 xenograft model was derived from a newly diagnosed
stage 3 abdominal NB in a 5-year-old boy, by direct subcutaneous
transplantation of small tumour fragments into previously
irradiated athymic mice (Vassal et al, 1996). The primary tumour
of this patient was refractory to conventional chemotherapy that
included platinum compounds, cyclophosphamide, doxorubicin,
etoposide and vincristine. IGR-NB8 exhibited the classic micro-
scopic appearance of an immature NB. In addition, this model
elicited a high tumorigenicity (99%) and a mean tumour doubling
time (DT) in vivo of 3.3 days. This xenograft displayed the
biological features of poor-prognosis NB in children: MYCN
amplification, near-diploid karyotype and chromosome 1p dele-
tion. In addition, the karyotype showed pericentric inversion of
chromosome 2 and additional material on the long arm of
chromosome 6. The MDR1 gene was overexpressed. IGR-NB8
proved to be sensitive in vivo to CPT-11, topotecan, cyclopho-
sphamide and cisplatin, but refractory to etoposide (VP16) (Vassal
et al, 1996, 1997).
Tumour transplantation
For each experiment, 15–30mm
3 tumour fragments were xeno-
transplanted subcutaneously (unilaterally) into 50 athymic mice.
On day 0 of the treatment, mice bearing a 100–300mm
3
subcutaneous tumour were randomly assigned to one treated
and one control group of five to 10 mice each. Tumour
perpendicular diameters were measured twice a week with a
caliper, and tumour volume calculated according to the following
equation: V (mm
3)¼(d
2 (mm
2) D (mm))/2, where d and D are
the smallest and largest perpendicular tumour diameters, respec-
tively. Each group of mice was treated according to the average
weight of the group. Animal body weights were recorded twice
weekly and mortality was checked daily. The experiments lasted
until tumour volumes reached 1500–2000mm
3.
Treatment
CPT-11 was administered i.v. in a caudal vein at a dose of
27mgkg
 1day
 1 for 5 consecutive days. This dose was previously
shown to induce 100% complete regressions (CR) and to be well
tolerated (no treatment-related death and no body weight loss)
(Vassal et al, 1996). This treatment was repeated every 21 days
(one cycle) for a maximum of four consecutive cycles (one
passage). During the establishment of in vivo resistance, the
treatment was stopped either after the fourth cycle or when 50% of
the tumours had reached a volume that was five-fold the initial
volume. After tumour regrowth following discontinuation of
treatment, tumour fragments were xenotransplanted subcuta-
neously into a new set of 50 athymic mice and the treatment was
started according to the same methodology.
Four anticancer compounds were studied to evaluate cross-
resistance phenotypes. Topotecan was administered i.p. daily 5
at a dose of 3.2mgkg
 1day
 1. Etoposide was administered i.v.
daily 5 at a dose of 20mgkg
 1day
 1. Cyclophosphamide was
administered as a single i.p. injection at a dose of 400mgkg
 1.
Cisplatin was administered i.v. on days 0 and 4 at a dose of
10mgkg
 1day
 1. Topotecan, cisplatin and etoposide were given at
the highest nontoxic dose and cyclophosphamide was given at 90%
of the historical LD10 dose, as previously evaluated in athymic
mice (Vassal et al, 1996, 1997).
Evaluation of antitumour activity
The activity of each drug was evaluated according to three criteria:
(1) the number of complete (CR) and partial (PR) tumour
regressions; (2) the TGD; (3) the number of tumour-free survivors
(TFS) (Bissery and Chabot, 1991). CR was defined as a tumour
regression beyond the palpable limit (15mm
3) and PR as a tumour
regression exceeding 50% of the initial tumour volume. At least
two consecutive tumour measurements had to be observed in
order to retain CR and PR. TGD was defined as the difference
between the treated group and the control group, within the
median time to reach a tumour volume that was five-fold the initial
tumour volume (i.e. time to 5). For each tumour of the treated
groups, the individual TGD was defined as the difference between
the individual time to 5 and the median time to 5 of the control
group. Since the duration of treatment was different from one
passage to another, we also considered the TGD, corrected for the
duration of treatment (TGDc), which was defined as the difference
between TGD and the duration of treatment. TFS were defined as
animals that were free of palpable tumour at the end of the
experiment (at least 120 days).
Histological analysis
Xenograft tissue specimens were fixed in acetic acid–formalin–
ethanol (Carlo-Erba, Milano, Italy) and embedded in paraffin. The
paraffin-embedded sections were stained with haematoxylin–
eosin–saffranin for morphology.
MYCN amplification
MYCN copy number was measured using the TaqMan 50 nuclease
fluorigenic real-time quantitative PCR assay, as reported pre-
viously (Valent et al, 2001).
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sComparative genomic hybridisation (CGH)
CGH was used to evaluate and characterise the genetic anomalies
acquired during the establishment of the resistant phenotype.
Genomic DNA from sensitive and resistant tumours at passages 1
and 24 was purified using the DNeasy tissue Kit (Qiagen).
Hybridisation of differentially labelled tumour and normal DNA
to normal metaphase chromosomes was performed using pre-
viously published methods (Kallioniemi et al, 1992). Digital image
analysis was used so that chromosomal regions with abnormal
fluorescence ratios could be easily identified. The mean values of
individual ratio profiles were calculated from at least 10
metaphases for each tumour specimen. CGH profile shifts were
rated as gains and losses if they at least reached the 1.20 and 0.8
thresholds, respectively.
Protein expression analysis
Crude extracts were prepared from NB xenografts. Frozen tissues
(50mg) were grossly minced, suspended in lysis buffer (containing
0.15 NaCl, 1mM KH2PO4,5m M MgCl2,1m M EDTA pH 6.4, 1mM
phenylmethylsulphonyl fluoride, 1mM dithiothreitol, 1mM benza-
midine, 1mgml
 1 aprotinine, 10mgml
 1 soybean trypsin inhibi-
tor) and homogenised with a potter teflon-glass homogeniser.
NaCl (0.55 M) was added and incubated for 1h on ice for total cell
extraction. After centrifugation at 12000r.p.m. for 30min, the
supernatant was assayed for topoisomerase I activity. Protein
concentration was determined by the BCA method (Pierce).
Proteins (50mg) were separated electrophoretically in 7.5% SDS–
polyacrylamide gels and then transferred to a nitrocellulose
membrane (Hybond P Amersham Life Science Les Ulis, France).
Blots were incubated with human polyclonal topoisomerase I
antibody (Topogen INC) diluted at 1:8300 followed by the anti-
protein A horseradish-peroxidase-conjugated antibody (Amer-
sham Pharmacia Biotech). Detection was performed using a
chemiluminescence (ECL) enzyme immunoassay (Amersham
Pharmacia Biotech).
Determination of topoisomerase I catalytic activity
Topoisomerase I catalytic activity of crude extracts was examined
by a DNA relaxation assay using supercoiled pHOT1 plasmid DNA
as the substrate (Topogen Inc., Columbus, OH, USA). For each
sample, 10 extracts were serially diluted in buffer containing 10mM
Tris-HCl, 100mM Kcl, 1mM PMSF, and 50mgml
 1 BSA, pH 7.5.
Supercoiled DNA (0.5mg) was incubated with each diluted extract
at 371C for 30min in 10 Topoisomerase I assay buffer (Topogen
Inc). DNA topoisomers were separated by gel electrophoresis in
1.25% agarose and stained with ethidium bromide. One arbitrary
unit of topoisomerase I activity was defined as the amount of
topoisomerase I showing relaxation of 0.25mg DNA under the
above-described conditions. Topoisomerase I activity was ex-
pressed in arbitrary units (a.u.) per mg of protein.
ATP-binding cassette (ABC) transporter superfamily
analysis
MDR1 and MRP1 mRNA expression was analysed by RT–PCR as
reported previously (Vassal et al, 2003b). The relative expression
ratios (RER) were calculated by dividing the fluorescence intensity
of the target gene band by that of the GAPDH control gene band.
Breast cancer resistance protein (BCRP) analysis was performed by
immunohistochemistry. Formalin-fixed paraffin-embedded tu-
mours were cut into 4-mm thick sections and rehydrated. Sections
were prepared with the Histo-mouse kit (Zymed) according to the
manufacturer’s instructions, and incubated for 1h at room
temperature with mouse anti-BCRP BXP-21 monoclonal antibody
(Chemicon international) diluted at 1:20. Detection was per-
formed using a rabbit anti-mouse IgG horseradish peroxidase
conjugate. A further analysis of BCRP expression was performed
by Northern blotting. Total RNA was prepared using Trizol
reagent, according to the manufacturer’s instructions. In all, 20mg
of total RNA were fractionated on a 1% agarose–formaldehyde gel
and subsequently transferred to a nitrocellulose membrane filter
(Hybond N Amersham Life Science Les Ulis, France). Blots were
prehybridised for 1h at 421Ci n5 SSC (1 SSC¼150mM sodium
chloride, 15mM sodium citrate, pH 7.0), 5 Denhardt’s solution,
0.2% SDS, 100mgml
 1 salmon sperm DNA and 50% deionised
formamide. The blots were then probed using 25ng of the
32P-
labelled BCRP/MXR/ABCP probe at 421C overnight. After washing
in 1 SSC/0.1% SDS for 20min at room temperature and three 10-
min washes with 0.2 SSC/0.1% SDS at 651C, blots were analysed
using a phosphor imaging system (Fujix Bas 2000).
RESULTS
Acquisition of in vivo resistance to CPT-11
The influence of CPT-11 treatment on the growth of the IGR-NB8
xenografted tumour over 28 passages is shown in Figure 1. The
tumour volume of all untreated controls increased rapidly. During
the first three passages, the same total dose of CPT-11
(540mgkg
 1) was administered over the same period of time (68
days) and tumour growth displayed the same pattern. Complete
regression and PR were observed after the first cycle of treatment.
Tumour volumes remained stable during the following three
cycles. When treatment was discontinued, tumours remained
stable for about 1 month and then started to grow again. Over the
first three passages, IGR-NB8 tumour response to CPT-11 was
significantly reduced with a TGD from 115 to 69, that is, a TGD
corrected for the duration of treatment from 47 days at the first
passage to 1 day at the third passage (Table 1). In contrast, neither
complete or partial tumour regression nor any tumour stabilisa-
tion were observed beyond the third passage (Table 1 and Figure 1).
At each passage, CPT-11 treatment was stopped as soon as at least
50% of tumours had reached a volume that was five-fold the initial
Table 1 Antitumour activity of i.v. CPT-11 at dose of 27mgkg
 1day
 1 against IGR-NB8 xenografts
Passages Number of cycles Total dose (mgkg
 1) Treatment duration (days) DT (days) CR
a PR
a TGD (days) TGDc (days) TFS
P1  4 540 68 7.1 3/7 4/7 115 47 0
P2  4 540 68 8.5 3/14 8/14 97 29 1
P3  4 540 68 8.3 2/14 7/14 69 1 1
P6  3 405 47 3 0/13 0/13 54 7 0
P9  3 405 47 3.7 0/8 0/8 47 0 0
P12  2 270 26 4.6 0/7 0/7 29 3 0
P15  2 270 26 7 0/10 3/10 27 1 0
P20  2 270 26 2.4 0/8 0/8 28 2 0
P28  2 270 26 6.1 0/8 0/8 17 0 0
DT¼doubling time; TGD¼tumour growth delay; TGDc¼tumour growth delay corrected for treatment duration; TFS¼tumour-free survivors at 120 days.
aCR,
PR¼complete and partial regression, at first cycle
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reduced from 4 to 2, the total dose from 540 to 270mgkg
 1 and the
duration of treatment from 68 to 26 days from passages 3 to 28.
Overall, the TGD was significantly reduced from 115 to 17 days
after 28 in vivo passages and 68 cycles of treatment. Tumour
DT gradually decreased during these 68 cycles of treatment.
We had established a NB xenograft that was resistant to CPT-11
(IGR-NB8-R).
Reverted resistance
In order to evaluate the stability of the resistance acquired, IGR-
NB8-R tumours at passage 8 were further grown without
treatment, while the prolonged treatment process was continued
in parallel up to 28 passages. Sensitivity to CPT-11 was checked
regularly (every 3–4 passages) by evaluating the TGD after one
cycle (27mgkg
 1 5) of treatment. As shown in Figure 2, the
resistance acquired in vivo during the first eight passages was
completely reverted after 15 growth passages of IGR-NB8-R
without any further exposure to CPT-11. Thus, in vivo acquired
resistance to CPT-11 was revertible.
Cross-resistance
In order to evaluate cross-resistance to other anticancer drugs in
vivo, IGR-NB8-R xenografts (between passages 8 and 11) were
grown in athymic mice. The sensitivity of the parental tumour
(IGR-NB8) and the resistant tumour (IGR-NB8-R) to other
anticancer drugs is shown in Figure 3. IGR-NB8-R and IGR-NB8
displayed similar tumour response to cyclophosphamide, an
alkylating agent, (TGD, 24 days) and to cisplatin (TGD, 16 days).
Conversely, IGR-NB8-R and IGR-NB8 failed to respond to
etoposide, a DNA-topoisomerase II inhibitor. However, IGR-
NB8-R was significantly less sensitive to the DNA-topoisomerase I
inhibitor topotecan (TGD, 13 days) than the parental IGR-NB8
(TGD, 26 days at 2.7mgkg
 1) (Vassal et al, 1997). Thus, IGR-NB8-
R exhibited cross-resistance to topoisomerase I inhibitors, but not
to DNA-damaging agents.
Characterisation of IGR-NB8-R
Fresh tumour tissues were collected from the parental xenograft
and from the resistant xenograft at passages 17–20. The parental
xenografts displayed the histological features of a poorly
differentiated NB composed of undifferentiated neuroblastic cells
(small uniform rounded cells) containing a high number of mitotic
figures per high-power field and very little schwannian stroma
(Figure 4A). During the first two passages, the stabilisation state
was associated with tumour differentiation exhibiting features of a
maturing ganglioneuroma (Santos et al, 2004) However, the IGR-
NB8-R-resistant xenografts showed similar histological features to
those observed in the parental xenografts (Figure 4A), namely
those of a poorly differentiated NB (Figure 4B). These results
indicate that there was no modification of histological features
during the acquisition of resistance.
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Figure 1 Evolution of the mean tumour volume during 28 consecutive passages. Animals received either saline (dotted line) or CPT-11 at a dose of
27mgkg
 1day
 1 (full line). Arrows represent the daily i.v injection.
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Figure 2 Effect of one cycle of CPT-11 27mgkg
 1day
 1 5. Passage 1
(P1 – sensitive tumour) and passage 8 (P8 – resistant tumour): treatment
discontinued in passage 8 (P8). P8P6 and P8P15: resistance verified in vivo
at P8P6 (P6¼6 passages without treatment after passage 8 with
treatment); P8P15 (P15¼15 passages without treatment after passage 8
with treatment). Central bars: medians.
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Neuroblastomas that overexpress MYCN due to amplification of
the MYCN oncogene are aggressive tumours that become resistant
to chemotherapy. High expression of MRP1 RNA has been
reported to be associated with MYCN amplification and poor
treatment outcomes (Norris et al, 1996). Analysis of the MYCN
oncogene in IGR-NB8-R xenograft showed that in spite of very
heterogeneous expression in a given passage, there was no major
difference, between MYCN amplification at P1 (sensitive tumour),
P9 (resistant tumour) and P8P16 (reverted tumour) exhibiting a
median value of 26.5, 25, and 20 copies per haploid genome,
respectively (Figure 5). However at passage 24 (resistant tumour),
MYCN amplification was double that of the other passages studied.
A fluorescence in situ hybridisation analysis showed that MYCN
was amplified in double minute form in the nucleus, which
explains the heterogeneous amplification observed. This is a
current situation observed in primary tumours (Valent et al, 2001).
Furthermore, in parallel of the 28 passages carried out to obtain
the IGR-NB8-R-resistant tumour, the IGR-NB8 xenograft was also
maintained during the same period without any treatment. MYCN
amplification analysis revealed a heterogeneity and a trend to a
time-dependent increase in copy number, according to the passage
number (Figure 5). Thus, the apparent increase in MYCN copies
observed in IGR-NB8-R overtime seems to be the consequence of a
selective growth advantage procured by increase of the number of
copies of MYCN rather than directly related to the prolonged
exposure to irinotecan.
CGH analysis
CGH analysis detected the same genomic imbalances in IGR-NB8
at P1 and IGR-NB8-R tumours xenografts at P24: partial
chromosome loss was observed at 1p32-pter, 6q25–27, 17p and
22. Partial chromosome gains were observed at chromosome
bands 2p23–24, 12p13 and 17q. These genomic imbalances are
characteristic in NB cell lines and advanced-stage tumours.
However, gains on chromosome 2p24 peaked on IGR-NB8-R, as
a result of an increased MYCN copy number at passage 24.
Analysis of topoisomerase I
Topoisomerase I catalytic activity was quantified in four to five
tumours at passages 1, 5, 11 and 13. (Figure 6). The average
topoisomerase I activity was 746972351, 703674952, 741071405
and 53347655a.u.mg
 1 (mean7s.d.), respectively. The modifica-
tions of topoisomerase I catalytic activity was not significant over
these passages, while TGD decreased from 115 to 32 days.
Moreover Western blot analysis of topoisomerase I showed no
difference between the tumours studied (Figure 7). The human
polyclonal anti-topoisomerase I antibody revealed two main bands
located at 100kDa, corresponding to a full-length enzyme and at
54kDa, a form specific to human tissues (Santos et al, 2004) and
perhaps the heavy chain of the immunoglobulin molecule
(Bronstein et al, 1996). Thus, topoisomerase expression and
activity was not implicated in the in vivo resistance acquisition.
ABC transporter superfamily analysis
MDR1 and MRP1 expression was quantified by RT–PCR before
treatment (P1) and at passages 6 (P6) and 11 (P11). Three tumours
were studied at each passage. MDR1-mRNA expression was
detected in all tumour samples. As compared to GAPDH-mRNA
expression, the MDR1-mRNA RER was 1.1770.46, 1.3870.43 and
1.2370.26 at P1, P6 and P11, respectively. These levels of relative
expression were comparable with the positive control MCF7
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Figure 3 Cross-resistance analysis. IGR-NB8 and IGR-NB8-R xenograft
tumours were treated with topotecan (3.2mgkg
 1day
 1), cyclopho-
sphamide (400mgkg
 1), cisplatin (10mgkg
 1day
 1) and etoposide
(20mgkg
 1day
 1). Central bars: medians.
Figure 4 HES staining for morphology of the parental (A) at passage 1
and NB resistant to CPT-11, IGR-NB8-R (B) xenografts at passage 17.
Original magnification  400.
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Figure 5 Amplification of MYCN oncogene by quantitative real-time
PCR. IGR-NB8-R xenograft under exposure to irinotecan [K] at passages
1, 9 and 24; reverted IGR-NB8-R P8P16 [E] after 16 passages without
treatment with irinotecan; IGR-NB8 xenograft grown in parallel to IGR-
NB8-R [J] at P1, between P5–P15 and P33–P39. Each symbol
represents one tumour.
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with an RER of 2.470.05, 1.9170.36 and 2.0870.75 at P1, P6 and
P11, respectively. These levels of relative expression were
comparable to that of A549, the positive control (2.8670.71).
These results confirmed the strong basal expression of MDR1 and
MRP1 in IGR-NB8. However, expression of both MDR1 and MRP1
did not increase from P1 to P11, while the TGD was being
significantly reduced from 115 to 25 days. Immunohistochemical
analysis of BCRP revealed relatively high expression in the positive
control (human placenta), and the absence of BCRP expression in
sensitive, resistant and chemosensitivity-restored tumours. North-
ern blotting confirmed these results. BCRP/MXR/ABCP mRNA was
undetectable in all the tumours analysed at various passages (P1,
P3, P7, P12, P18, P21 and P8P15). The positive control (T8 cells)
(Maliepaard et al, 1999) overexpressing BCRP mRNA and GAPDH
were very positive in all tested samples (data not shown). Thus,
CPT-11 resistance in vivo in IGR-NB8-R xenograft is not related to
MDR1, MRP1 and BCRP expression.
DISCUSSION
Irinotecan has shown activity against colorectal, oesophageal,
gastric, non-small-cell and small-cell lung cancer, leukaemia and
lymphomas, as well as central nervous system malignant gliomas
(Rothenberg, 2001). One of the major hurdle to clinical develop-
ment of active agents is intrinsic or acquired chemoresistance. To
date, the mechanisms that confer clinical resistance to camptothe-
cin have not been characterised. In the field of oncology,
knowledge of drug resistance mechanisms is based largely on in
vitro studies. Several cell lines selected for resistance to irinotecan
have been described and these studies have shed light on
mechanisms such as topoisomerase I alteration or increased efflux
of irinotecan from the cell (Xu and Villalona-Calero, 2002).
However, in vitro analyses of resistance mechanisms remain
limited. The majority of the variables are controlled and cellular
interactions are not taken into account. Moreover, in vivo and in
vitro phenotype of cancer cells do not always coincide. Teicher et al
derived a series of alkylating agent-resistant variants (cis-
diamminedichloroplatinum, cyclophosphamide, carboplatin and
thiotepa) of the EMT-6 mouse mammary tumour through in vivo
drug administration to syngeneic BALB/c tumour-bearing mice.
The resistance observed was reversible after discontinuation of
treatment, as demonstrated in our model. In spite of high levels of
resistance in vivo, no significant resistance was observed when the
cells from these tumours were exposed to the drugs in vitro,
indicating that a very high level of resistance to anticancer drugs
can develop through mechanisms that are exclusively in vivo
(Teicher et al, 1990). Furthermore, Kobayashi et al (1993) have
suggested that some forms of acquired drug resistance operate
only at the multicellular level, as opposed to classic unicellular
resistance mechanism.
Thus, our first objective was to establish a subcutaneous NB
xenograft model that is resistant to CPT-11. After a series of 68
cycles of CPT-11 treatment and 28 passages in vivo, IGR-NB8
showed the characteristics of a CPT-11-resistant tumour. First, no
CR or PR was observed after the third passage, whereas the
treatment induced 100% of CR and PR at the first passage. Second,
during passaging, a very significant decrease (from 115 to 17 days)
was observed in the TGD. Third, the number of consecutive cycles
that were required for 50% of tumours to attain five-fold their
initial volume was reduced from four to two cycles. The CPT-11-
resistant IGR-NB8 NB model was designated IGR-NB8-R.
To our knowledge, only one model of in vivo acquired resistance
to CPT-11 has been reported, which is also an in vivo NB (NB-
1691) model established by Thompson et al. After four rounds of
treatment/transplantation (5mgkg
 1administration
 1), authors
observed a resistance to irinotecan and a partial resistance to
topotecan. The mechanisms of resistance were not discussed in
this paper (Thompson et al, 2002, p 541). Our in vivo model of
acquired resistance evaluated in a therapeutic setting will allow us
to confirm and clarify resistance mechanisms observed in vitro or
to discover new resistance mechanisms by taking into account
cellular interactions and thus rendering this approach more
realistic from a clinical point of view.
First, IGR-NB8-R was characterised by the absence of cross-
resistance to DNA-damaging agents and the presence of cross-
resistance to another topoisomerase I inhibitor, topotecan. Both
CPT-11 and topotecan are topoisomerase I inhibitors, which
suggests a common resistance mechanism. Altering the topoi-
somerase I, the common target of these two drugs, can modify
treatment efficacy. For example, some camptothecin-resistant cell
lines have a mutation in topoisomerase I and this mutation may
affect, the catalytic activity of the enzyme (Fujimori et al, 1995), or
alter interactions with camptothecin or DNA cleavage (Li et al,
1996). In our xenograft model, however, qualitative or quantitative
modifications of topoisomerase I cannot be responsible for the
IGR-NB8-R resistance to CPT-11 and topotecan because no
modification of topoisomerase I activity was demonstrated during
the analysis with the DNA relaxation assay and the Western blot
analysis showed no difference in topoisomerase I expression
during the acquisition of resistance. Furthermore, the acquired
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Figure 6 Catalytic activity of topoisomerase I at passages 1, 5, 11 and 13.
Each symbol represents one tumour. Horizontal bars: medians.
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Figure 7 Topoisomerase I analysis by Western blot at passages 1, 5, 11
and 13. Protein from tissue homogenates, 50mg, were separated in 7.5%
SDS–polyacrylamide gels, transferred to a nitrocellulose membrane and
immunoblotted with human polyclonal topoisomerase I antibody (Topogen
Inc.).
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recovered its initial sensitivity after 15 passages without treatment.
This suggests a resistance mechanism that is induced and
maintained by CPT-11 and not a phenomenon such as mutation,
which is not readily reversible.
We then evaluated the multidrug resistance phenomenon
attributed to a change in drug efflux that could explain the
cross-resistance of IGR-NB8-R to topotecan and CPT-11. Trans-
membrane proteins, belonging to the ABC superfamily, participate
in energy-dependent drug efflux and confer multidrug resistance.
Some transporters in this family, such as MRP and MDR1 that are
involved in the active efflux of SN-38 and CPT-11, contribute to
resistance to CPT-11 (Chu et al, 1999). Furthermore, in NB, it has
been reported that high MRP RNA expression was associated with
MYCN amplification and poor treatment outcomes (Norris et al,
1996). However, although the basal expression level of MDR1 and
MRP1 was strong in sensitive tumours in our study, it did not
increase during the acquisition of resistance. Maliepaard et al
showed that BCRP, which also belongs to the ATP-binding cassette
transporter family, appears to be a highly efficient transporter of
topoisomerase I inhibitors in cell lines without overexpression of
the multidrug resistance-associated pumps MDR1 and MRP1
(Maliepaard et al, 1999). Furthermore, van Hattum et al (2002)
showed that DX-895, a derivative of camptothecin, is able to
induce BCRP protein as a mechanism of resistance in the human
ovarian cell line A2780. In our resistant model, which does not
overexpress MDR1 or MRP1, we hypothesised that overexpression
of BCRP could explain IGR-NB8-R resistance to irinotecan and
topotecan without quantitative or qualitative modifications of
topoisomerase I activity. This hypothesis prompted us to study
BCRP expression; however, like MDR1 and MRP1, no over-
expression of BCRP was demonstrated during the acquisition of
resistance.
Among the various mechanisms of resistance to irinotecan
characterised in vitro, we could eliminate those that were usually
observed, such as intracellular drug accumulation or drug-target
interaction. More recently, nuclear factor kappa B (NFkB)
activation was shown to play a role in sensitivity to this drug;
treatment with camptothecin was reported to activate NFkB (Wang
et al, 1999; Cusack et al, 2000; Huang et al, 2000). Furthermore, the
cytotoxic effect of SN-38 was strongly increased through the
inactivation of NFkB. The apoptotic response mediated by CPT-11
was dependent on NFkB inhibition, establishing NFkBa sa
principal mediator of inducible chemoresistance (Wang et al,
1999). We are currently exploring the potential role of NFkB in our
model of acquired resistance to CPT-11.
We have established a human NB xenograft resistant to CPT-11.
This resistance mechanism seems to be novel. It does not imply
any of the mechanisms of resistance usually observed in in vitro
preclinical studies. Furthermore, it is a revertible mechanism that
probably does not imply mutations. Our next objective is to
investigate the basis of this mechanism of acquired drug
resistance. Several genes are likely implicated; therefore, a genomic
comparison of the transcriptome of sensitive and resistant
tumours with macro- and microarray is in progress. This
technology will allow us to rapidly identify differences in
expression between genes. Clarifying the resistance mechanism
in IGR-NB8-R will allow us to make a step forward in our
understanding of acquired chemoresistance and to better target the
clinical development of irinotecan.
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